|Study Description:||The goal of Phase 1 of this clinical research study is to find the highest |
tolerable dose of elotuzumab that can be given in combination with bortezomib,
lenalidomide, and dexamethasone to patients with MM.
The goal of Phase 2 of this study is to learn if adding elotuzumab to the
combination of bortezomib, lenalidomide, and dexamethasone can help to control
Bortezomib is designed to block a protein that plays a role in how cancer cells
divide. This may affect cell function and growth and may cause cancer cells to
Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. Therefore, it may decrease or prevent the growth of cancer cells.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.
Elotuzumab is a type of protein called a monoclonal antibody that is designed
to attach to a protein on the surface of MM cells, which may cause them to die.